
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences is currently valued at $9.3B due to its positive outlook as a company. With a 90% probability of approval for bezuclastinib in advanced systemic mastocytosis, a 95% POA in non-advanced systemic mastocytosis, and a 90%POA in the 2L GIST indication, this shows strong potential for success in the biotechnology market. However, there are risks that must be considered, such as negative clinical data, setbacks in later-stage trials, failure to obtain regulatory approvals, and lower than projected commercial success.
Bears say
Cogent Biosciences is expected to submit an NDA for its lead program bezuclastinib, a precision therapy for systemic mastocytosis and GIST, in the coming months. FDA's Real-Time Oncology Review program may expedite this process, potentially leading to an approval in 2026. However, potential risks include unsuccessful clinical results, competition from other treatments, and regulatory or commercial challenges. With a strong balance sheet and multiple programs in its pipeline, COGT may be a good long-term investment opportunity for buyers looking to capitalize on its potential success in the precision therapy market.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares